Description

Charles River Targets $375–$400 Million Free Cash Flow Despite A Weak Q1; Will It Work?

Charles River Laboratories delivered its first-quarter 2026 financial results in line to slightly above prior expectations, amid discrete margin pressures and ongoing industry challenges. The company reported total revenue of $996 million, which reflected a 1.5% organic decline, consistent with their guidance. Non-GAAP operating margin decreased 280 basis points to 16.3%, influenced primarily by higher stock compensation related to the CEO transition, increased costs associated with non-human primate (NHP) sourcing and study starts in the Drug Safety Assessment (DSA) segment, as well as timing issues impacting NHP revenue and lower shipment volumes in the Research Models and Services (RMS) segment. Non-GAAP earnings per share decreased 12% to $2.06 but exceeded expectations, aided by stronger-than-anticipated results in the Manufacturing and RMS segments. Segment performance was mixed. The DSA segment experienced a 1.4% organic revenue decline driven by lower Discovery Services revenue, with Safety Assessment services largely stable. RMS revenue declined 5.